Market Overview

AccuVein Announces Record Year with More Than 40% Growth in Domestic Sales


Growth Fueled by Accelerated Adoption and Reorders

(PRWEB) January 16, 2015

AccuVein Inc., the global leader in vein visualization, announced today that domestic sales grew over 40% year over year. This sales growth was achieved through a combination of new customers who have embraced vein visualization and existing customers who are reordering additional devices.

This growth in sales brings the number of U.S. hospitals in which AccuVein is in use to almost 2,000. In addition 100 percent of the 17 hospitals that U.S. News and World Report named as the nation's best hospitals are AccuVein customers.

“We are thrilled with our 2014 results,” said AccuVein CFO Chuck Johnson, “AccuVein not only had a stellar 2014 but they are well situated to continue this momentum in 2015.”

The use of vein visualization in facilities around the country has gained significant traction this year with the recommendation by the Infusion Nurses Society of vein visualization in their 2014 guidelines that “Vein visualization can improve success rates, decrease unsuccessful insertion attempts and improve patient satisfaction.” Also studies completed this year showed a striking 45% reduction in escalation calls following the implementation of the AccuVein AV400, with 81% of nurses reporting an improved ability to cannulate veins.

AccuVein's vein illumination device is also available for sale in 120 countries worldwide. For the full list of countries, please visit

About AccuVein Inc.
AccuVein Inc. is the global leader in vein visualization. AccuVein is the world's only hand-held, non-contact vein illumination solution. It allows healthcare professionals to see a map of peripheral veins on the skin's surface with the goal of accessing or avoiding veins. It is built on proprietary technology as embodied in its growing patent portfolio that covers a broad range of imaging and medical diagnostic technologies. To see a demonstration of AccuVein in action, please visit

For the original version on PRWeb visit:

View Comments and Join the Discussion!